Arie Belldegrun

Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M

LA500 2026: Arie Belldegrun

49. Arie Belldegrun

Arie Belldegrun: A Tribute to the Founding Father of CAR T Dr. Zelig Eshhar

LA500 2025: Arie Belldegrun

Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship

50. Arie Belldegrun

Inside Arie Belldegrun’s $600M life sciences credit firm Symbiotic Capital

Biotech entrepreneur Arie Belldegrun launches new ‘science-first’ credit firm

Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm

STAT+: Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm

LA500 2024: Arie Belldegrun

Biopower Player: Arie Belldegrun

How Arie Belldegrun is still charting his path to serial success

Arie and Dan Belldegrun are building biotech campuses around the globe — with a newly raised $3B fund to keep the dirt flying

Arie Belldegrun’s venture capital firm raises third and largest fund

Belldegrun's VC firm nabs a major $825M funding well for next

Arie Belldegrun’s Vida Ventures snaps up $825M to spend on cutting-edge R&D

Dr. Arie Belldegrun, Co-Founder and Executive Chairman, Allogene Therapeutics

Tishman Speyer, Bellco start life sciences firm

Doctor who sold $12 billion drug firm eyes biotech property

Doctor Who Sold Drug Firm for $12 Billion Eyes Biotech Property

Arie Belldegrun, MD

Arie Belldegrun, building out his new CAR-T startup, pursues senior biotech sell

They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again

Kite chief Arie Belldegrun up for $600M